vTv Therapeutics (VTVT) AI Stock Analysis

• Market Cap: $144.89M
• Dividend Yield: N/A
• Average Volume (3M): 5.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: -98.30%
• EPS Growth: 26.62%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 3,938,018
• 10 Day Avg. Volume: 5,801
• 30 Day Avg. Volume: 5,072
• PEG Ratio: 0.06
• Price to Book (P/B): 6.53
• Price to Sales (P/S): 78.37
• P/FCF Ratio: -3.15
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -300.12
• Enterprise Value/Gross Profit: 1.02K
• Enterprise Value/Ebitda: 0.18
• 1Y Price Target: $55.25
• Price Target Upside: 59.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -3.98
• Revenue Forecast (FY): $4.00M

• Rating: 48 Neutral
• Price Target: $35.00 ▲(0.95% Upside)
• Action: Reiterated Date: 02/02/26
• Date: Action: Reiterated 02/02/26

Score is held back primarily by very weak financial performance—minimal revenue, large ongoing losses, and persistent cash burn—despite low debt. Technicals are mixed (longer-term trend above key moving averages but softer near-term momentum), and valuation is constrained by negative earnings. A notable positive is the recent partnership amendment that could provide meaningful non-dilutive funding and milestone/royalty upside.

Positive Factors

Partnerships / Non-dilutive Funding

The Newsoara amendment provides meaningful non-dilutive capital and milestone/royalty upside tied to HPP737 commercialization. Structurally this reduces near-term financing pressure, aligns partner commercialization incentives, and enhances long-term funding optionality without immediate equity dilution.

Low Financial Leverage

Extremely low debt materially lowers bankruptcy and interest-rate risk for a pre-revenue biotech. This structural conservatism preserves flexibility to pursue partnerships or raise capital on favorable terms and limits fixed financial obligations during clinical development.

Focused R&D Pipeline

A concentrated strategic focus on small-molecule metabolic programs creates specialization advantages: domain expertise, streamlined trial design, and clearer partnering/commercialization pathways. This focus supports durable R&D execution and targeted licensing opportunities.

Negative Factors

Negligible Product Revenue

With virtually no product revenue, the company lacks recurring cash inflows to sustain operations. Over multiple quarters this structural revenue gap forces reliance on external financing or partners and leaves long-term viability contingent on trial success or licensing outcomes.

Persistent Cash Burn

Sustained negative operating and free cash flow indicates the business consumes capital to advance trials rather than generating it. Over a multi-month horizon this elevates refinancing and dilution risk, making execution dependent on continued access to partner payments or capital markets.

Dependence on External Financing

Sharp swings in shareholders' equity reflect financing-driven balance sheet changes rather than organic profitability. Structurally, this dependence on financings and occasional accounting step-ups increases dilution risk and ties the company's runway and program advancement to capital or partner milestones.

vTv Therapeutics Business Overview & Revenue Model

Company Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

How the Company Makes Money

vTv Therapeutics primarily generates revenue through partnerships and collaborations with other pharmaceutical companies. These collaborations often involve licensing agreements, wherein vTv licenses its proprietary drug candidates or technology platforms to partners in exchange for upfront payments, milestone payments based on development progress, and potential royalties on future sales. The company may also receive funding support through research grants and government incentives aimed at fostering innovation in the biopharmaceutical field. Additionally, vTv Therapeutics may engage in strategic alliances to co-develop and commercialize certain products, thereby sharing the financial risks and rewards associated with drug development.

vTv Therapeutics Financial Statement Overview

Summary

Financial profile is weak: revenue is essentially negligible (TTM ~$17K), gross profit is negative, and losses remain large (TTM EBIT about -$29.8M; net income about -$23.5M). Cash burn is persistent with negative operating and free cash flow (TTM operating cash flow about -$20.8M). Balance sheet leverage is low (TTM total debt about $0.36M) and equity is stronger in the most recent period, but the company remains reliant on external funding while operating at a significant deficit.

Income Statement

Results remain deeply loss-making with very weak profitability in both annual periods and TTM (Trailing-Twelve-Months). TTM revenue is essentially de minimis ($17K) and gross profit is negative, while operating losses are large (TTM EBIT about -$29.8M) and net losses remain substantial (TTM net income about -$23.5M). Revenue has not shown a sustained growth trajectory (including a year with zero revenue), and margins are highly negative, indicating limited operating leverage at the current scale. A modest positive is that losses have not consistently worsened every year, but overall earnings quality and visibility remain weak.

Balance Sheet

Leverage is low, with minimal total debt across periods (TTM total debt about $0.36M) and a very low debt-to-equity level in the most recent balance sheets, reducing near-term financial risk from borrowing. However, the equity picture has been volatile—stockholders’ equity was negative in multiple years before turning positive in 2024 and rising sharply in TTM (about $70.5M), suggesting meaningful financing activity and/or accounting step-ups rather than internally generated profitability. Returns on equity are very weak given ongoing losses, and the company remains dependent on external capital while it operates at a significant deficit.

Cash Flow

Cash generation remains a key weakness. Operating cash flow is consistently negative (TTM operating cash flow about -$20.8M), and free cash flow is equally negative, indicating ongoing cash burn to fund operations. While the burn rate improved versus 2024 (less negative in TTM), the longer-run trend is uneven and includes periods of higher outflows. Free cash flow is roughly in line with net losses, which suggests losses translate into cash burn rather than being primarily non-cash—raising the importance of funding access.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.00K	1.02M	0.00	2.02M	4.00M	6.41M
Gross Profit	-5.00K	1.02M	0.00	2.02M	4.00M	-4.60M
EBITDA	-28.96M	-22.52M	-25.86M	-24.77M	-17.52M	-12.02M
Net Income	-23.47M	-18.46M	-20.25M	-19.16M	-12.99M	-8.50M
Balance Sheet
Total Assets	99.49M	38.27M	11.02M	33.24M	25.47M	14.79M
Cash, Cash Equivalents and Short-Term Investments	98.50M	36.75M	9.45M	12.13M	13.41M	5.75M
Total Debt	360.00K	169.00K	529.00K	716.00K	932.00K	915.00K
Total Liabilities	28.95M	23.96M	29.57M	27.40M	10.25M	11.00M
Stockholders Equity	70.54M	12.20M	-24.68M	-10.74M	-9.74M	-80.10M
Cash Flow
Free Cash Flow	-20.83M	-25.31M	-19.08M	-15.27M	-19.31M	-18.00M
Operating Cash Flow	-20.83M	-25.31M	-19.08M	-15.25M	-19.31M	-18.00M
Investing Cash Flow	0.00	0.00	4.40M	-21.00K	0.00	0.00
Financing Cash Flow	77.76M	52.61M	12.00M	13.98M	26.98M	19.47M

vTv Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.67
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Negative. The current price of 34.67 is below the 20-day moving average (MA) of 35.71, below the 50-day MA of 36.42, and above the 200-day MA of 24.44, indicating a neutral trend. The MACD of 0.44 indicates Negative momentum. The RSI at 47.31 is Neutral, neither overbought nor oversold. The STOCH value of 31.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTVT.

vTv Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADAG	53 Neutral	$139.98M	-4.61	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VTVT	48 Neutral	$144.89M	-10.43	-54.87%	―	-98.30%	26.62%
ATHE	46 Neutral	$53.67M	-5.87	-42.68%	―	―	63.85%
CLNN	45 Neutral	$59.24M	-1.48	―	―	-49.17%	23.37%
IFRX	43 Neutral	$61.25M	-0.87	―	―	―	―
PLRX	42 Neutral	$76.81M	-0.44	-64.27%	―	―	14.19%

vTv Therapeutics Corporate Events

vTv Therapeutics Expands Global HPP737 Rights with Newsoara

On January 30, 2026, vTv Therapeutics LLC amended its 2018 license agreement with Newsoara Biopharma, restoring and significantly expanding Newsoara’s rights to develop and commercialize the PDE4 inhibitor HPP737 on a worldwide basis, contingent on a $20 million upfront payment. Under the revised terms, vTv stands to receive up to $50 million in development milestone payments, $65 million in sales-related milestones, and mid-single-digit royalties on sales, positioning the company to secure substantial non-dilutive funding and broader global exposure for HPP737, with potential upside for both its revenue profile and partnership-driven growth strategy.

The most recent analyst rating on (VTVT) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.